Nephrogenic diabetes insipidus

Overview and Pathophysiology

Nephrogenic diabetes insipidus (NDI) is a disorder of water metabolism characterized by the inability of the renal collecting ducts to concentrate urine in response to arginine vasopressin (AVP), also known as antidiuretic hormone (ADH).
Under normal physiological conditions, AVP binds to the vasopressin V2 receptor (AVPR2) located on the basolateral membrane of the principal cells in the collecting duct.
This binding activates a cyclic adenosine monophosphate (cAMP)-dependent cascade, which stimulates protein kinase A (PKA) to phosphorylate aquaporin-2 (AQP2) water channels.
Phosphorylated AQP2 channels are translocated from intracellular vesicles and inserted into the apical plasma membrane, rendering the collecting duct permeable to water and allowing for water reabsorption and urine concentration.
In NDI, a defect in either the AVPR2 receptor or the AQP2 water channel disrupts this pathway, resulting in the failure of water reabsorption and subsequent excretion of massive amounts of dilute urine.

Category	Specific Etiologies and Characteristics
Primary Congenital NDI (X-Linked)	Accounts for ~90% of congenital cases; caused by loss-of-function mutations in the AVPR2 gene located on the X chromosome. Female carriers are usually unaffected, but skewed X-inactivation can lead to complete manifestation of the disease in some females.
Primary Congenital NDI (Autosomal)	Accounts for ~10% of congenital cases; caused by mutations in the AQP2 gene. Can be inherited in an autosomal recessive or, less commonly, autosomal dominant pattern.
Secondary NDI (Monogenic Disorders)	NDI occurring as a secondary complication of other inherited tubulopathies, including Bartter syndrome, distal renal tubular acidosis (dRTA), cystinosis, and familial hypomagnesemia with hypercalciuria and nephrocalcinosis.
Acquired NDI (Electrolyte/Metabolic)	Severe hypokalemia and hypercalcemia can impair the medullary concentrating gradient or cause autophagic degradation of AQP2.
Acquired NDI (Drugs and Toxins)	Lithium toxicity is a major cause; lithium enters principal cells via the epithelial sodium channel (ENaC) and inhibits AQP2 expression. Other drugs include amphotericin B and foscarnet.
Acquired NDI (Structural/Urologic)	Chronic pyelonephritis, obstructive uropathy, sickle cell nephropathy, and cystic kidney diseases.

Pregnancies are typically not complicated by polyhydramnios, and infants have normal birth weights.
Manifestations emerge within the first weeks of life, but breastfed infants may initially thrive without signs of dehydration because human milk has a low salt and protein content (low renal osmole load).
Upon introduction of cow's milk formula, the increased osmole load demands more free water excretion, leading to rapid hypernatremic dehydration.
Initial symptoms include profound polyuria, polydipsia, irritability, inconsolability, poor feeding, recurrent vomiting, and failure to thrive.
Severe dehydration manifests with loss of skin turgor, recessed eyeballs, depressed anterior fontanelle, scaphoid abdomen, and intermittent high unexplained fevers.

Toddlers and older children exhibit profound polydipsia with a distinct preference for cold water.
The constant need to consume large volumes of water diminishes appetite and food intake, further contributing to severe growth retardation.
Daytime incontinence and nocturnal enuresis are nearly universal.
Chronic massive polyuria leads to severe urological complications in 40-50% of patients, including nonobstructive hydronephrosis, hydroureter, megacystis, and a trabeculated, hypotonic bladder.
Repeated episodes of hypernatremic dehydration and subsequent rapid rehydration can cause cerebral edema, leading to seizures, intracranial calcifications, and permanent intellectual disability, though neurodevelopmental outcomes have improved with modern proactive management.

The diagnosis is strongly suspected in an infant presenting with massive polyuria, hypernatremia, and inappropriately dilute urine.

Diagnostic Parameter	Typical Findings in NDI
Serum Chemistries	Marked hypernatremia (often >170 mEq/L), hyperchloremia, and elevated serum osmolality (>290-295 mOsm/kg).
Urine Chemistries	Urine osmolality is inappropriately low (typically <150-200 mOsm/kg) despite elevated plasma osmolality and severe clinical dehydration. Urine sodium is typically low.
Vasopressin Challenge Test	Following administration of 1-deamino-8-D-arginine vasopressin (DDAVP), patients with NDI fail to increase urine osmolality, which remains <200-300 mOsm/kg. This distinguishes NDI from central diabetes insipidus, where urine osmolality appropriately rises >600-800 mOsm/kg.
Water Deprivation Test	Formal water deprivation is contraindicated and not recommended in infants due to the high risk of rapid, life-threatening dehydration.
Plasma Copeptin	Used as a stable surrogate marker for AVP; plasma copeptin levels >20 pmol/L strongly suggest nephrogenic diabetes insipidus.
Renal Ultrasonography	Essential to evaluate for structural consequences of chronic polyuria, such as hydronephrosis or megacystis, and to exclude underlying obstructive uropathy or cystic diseases causing secondary NDI.
Genetic Testing	Direct sequencing of the AVPR2 and AQP2 genes confirms the exact molecular diagnosis and allows for genetic counseling and prenatal testing.

The cornerstone of therapy is the prevention of dehydration by ensuring continuous, unrestricted access to free water.
In infants, the use of a low-solute formula (such as Similac PM 60/40) or human breast milk is preferred to minimize the obligate renal osmole load.
Many young children require placement of a nasogastric tube or gastrostomy button to ensure adequate fluid administration and caloric intake throughout the day and night.
Dietary sodium restriction is recommended (typically <1 mEq/kg/day or <0.7 mEq/kg/day) to decrease the obligatory water excretion.
Severe dietary protein restriction is no longer routinely advised as it may introduce serious nutritional deficiencies and exacerbate growth failure.

Medication	Mechanism of Action and Clinical Utility	Limitations and Adverse Effects
Thiazide Diuretics (e.g., Hydrochlorothiazide)	Induces a state of mild extracellular volume contraction, which secondarily increases compensatory sodium and water reabsorption in the proximal tubule; reduces urine volume by 20-50%.	Can cause significant hypokalemia, which may paradoxically worsen the concentrating defect or precipitate cardiac arrhythmias.
Potassium-Sparing Diuretics (e.g., Amiloride)	Administered in combination with thiazides to prevent hypokalemia; particularly useful for lithium-induced NDI as it blocks the entry of lithium through the ENaC channels in the collecting duct.	May cause persistent nausea and gastrointestinal intolerance, especially in young children under 4-6 years of age.
Prostaglandin Synthesis Inhibitors (e.g., Indomethacin)	Prostaglandins normally antagonize the action of AVP; indomethacin reduces renal prostaglandin E2 production, thereby decreasing renal blood flow, enhancing proximal tubular reabsorption, and exerting an additive antidiuretic effect when combined with thiazides.	Carries a high risk of nephrotoxicity; can cause acute deterioration of renal function, especially during episodes of dehydration, and predisposes patients to chronic kidney disease or gastrointestinal bleeding.